BioLineRx (NASDAQ: BLRX) files Form 6-K with June 30, 2025 results

Rhea-AI Filing Summary

BioLineRx Ltd. filed a Form 6-K as a foreign private issuer for August 2025, reporting that it has released its financial results for the three and six months ended June 30, 2025. The submission includes a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for that period. These materials are incorporated by reference into all of the company’s effective registration statements under the Securities Act of 1933, meaning those registration statements now formally include the newly reported interim financial information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/14/2025 - 07:10 AM Learn about SEC filing dates

FAQ

What did BioLineRx (BLRX) file in this Form 6-K?

BioLineRx Ltd. filed a Form 6-K as a foreign private issuer, providing a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for the three and six months ended June 30, 2025.

Which period do BioLineRx (BLRX) interim financials in this filing cover?

The interim financial information covers the three and six months ended June 30, 2025, with condensed consolidated interim financial statements and an operating and financial review as of that date.

How are the BioLineRx (BLRX) June 30, 2025 results used in its registration statements?

The Form 6-K, the financial results section of the press release, the interim financial statements, and the operating and financial review are incorporated by reference into all of BioLineRx’s effective Securities Act registration statements.

What exhibits are included with this BioLineRx (BLRX) Form 6-K?

The filing includes Exhibit 1, a press release dated August 14, 2025; Exhibit 2, condensed consolidated interim financial statements as of June 30, 2025 and for the three and six months then ended; and Exhibit 3, an operating and financial review for the same period.

Who signed the BioLineRx (BLRX) Form 6-K and in what capacity?

The Form 6-K was signed on behalf of BioLineRx Ltd. by Philip A. Serlin, who is the Chief Executive Officer.

What type of annual report does BioLineRx (BLRX) file with the SEC?

BioLineRx files or will file its annual reports under cover of Form 20-F as a foreign private issuer.

0001498403false--12-31Q2

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission file number: 001-35223

BioLineRx Ltd.

(Translation of registrant’s name into English)

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On August 14, 2025, the Registrant issued a press release announcing its financial results for the three and six months ended June 30, 2025. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of June 30, 2025 and for the three and six months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated August 14, 2025;

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of June 30, 2025 and for the three and six months then ended; and

Exhibit 3: Registrant’s operating and financial review as of June 30, 2025 and for the three and six months then ended.

This Form 6-K, the text under the heading “Financial Results for the Quarter Ended June 30, 2025” in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.
	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: August 14, 2025